公开(公告)号：EP3845644B1

公开(公告)日：2024-04-24

申请号：EP20216964.5

申请日：2016-09-08

IPC: C12N15/09 ,  A61K38/00 ,  A61P5/10 ,  A61P19/00 ,  A61P43/00 ,  C07K14/765 ,  C07K19/00 ,  C12N5/16 ,  A61P3/00 ,  C07K14/61 ,  A61P5/06

CPC classification number: A61K38/00 ,  C07K19/00 ,  C12N5/16 ,  C12N15/09 ,  C07K2319/3120130101 ,  C07K14/765 ,  A61P43/00 ,  A61P3/00 ,  A61P5/06 ,  C07K14/61

公开(公告)号：EP3411079A1

公开(公告)日：2018-12-12

申请号：EP17746953.3

申请日：2017-01-26

Applicant: Nanjing Legend Biotech Co., Ltd.

Inventor： FAN, Xiaohu ,  ZHANG, Fangliang ,  ZHUANG, Qiuchuan ,  WANG, Pingyan ,  YU, Jie ,  HE, Xian ,  WANG, Lin ,  HAO, Jiaying ,  YANG, Lei

IPC: A61K48/00 ,  C12N5/16 ,  C12N5/22 ,  A61P35/00

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K16/00 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/73 ,  C12N5/16 ,  C12N2501/48 ,  C12N2501/51 ,  C12N2510/02 ,  C12N2740/16043

Abstract: Provided are pharmaceutical compositions comprising an engineered mammalian cell comprising a heterologous nucleic acid encoding an immunomodulator. Further provided are methods of treating cancer using the pharmaceutical composition either singly or in combination with other technologies, such as Chimeric Antigen Receptor (CAR) or recombinant T cell receptor (TCR) modified T cell immunotherapy.

公开(公告)号：EP2440654B1

公开(公告)日：2018-07-18

申请号：EP10785598.3

申请日：2010-06-10

Applicant: Stephen Sanig Research Institute Ltd.

Inventor： KASEKO, Galina ,  MAHAWORASILPA, Tohsak L.

IPC: C12N5/078 ,  C12N5/16

CPC classification number: C12N5/16 ,  C12N5/0634

Abstract: The present invention relates to cellular differentiation and, in particular to hybrid cells that exhibit phenotypic plasticity and methods for producing these cells. The invention also relates to methods for generating specific cells of a desired phenotype. The invention still further relates to methods of producing hybrid cells with a capacity to de-differentiate into an earlier progenitor state. The invention further contemplates the use of hybrid cells in a range of applications, for example tissue generation.

公开(公告)号：EP2362733B1

公开(公告)日：2017-04-12

申请号：EP09825528.4

申请日：2009-11-06

Applicant: Indiana University Research & Technology Corporation

Inventor： PELUS, Louis, M. ,  HOGGATT, Jonathan ,  SINGH, Pratibha

IPC: A61K38/19 ,  C12N5/0789 ,  A01N65/00 ,  C07C61/06 ,  A61K31/00 ,  A61K31/395 ,  A61K31/405 ,  A61K31/5415 ,  A61K35/14 ,  C12N15/16 ,  C12N9/02 ,  C12N15/63 ,  C12N15/86 ,  A61K31/4035 ,  A61K31/4196 ,  A61K35/12 ,  A61K35/28 ,  A61K35/50 ,  A61K35/51

CPC classification number: A61K35/14 ,  A61K31/00 ,  A61K31/395 ,  A61K31/4035 ,  A61K31/405 ,  A61K31/4196 ,  A61K31/5415 ,  A61K35/28 ,  A61K35/50 ,  A61K35/51 ,  A61K38/193 ,  A61K2035/124 ,  C12N5/0647 ,  C12N5/16 ,  C12N9/0083 ,  C12N15/63 ,  C12N15/86 ,  C12N2501/02 ,  C12Y114/99001

Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 re-ceptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to in- crease viral-mediated gene transduction efficacy into HSPC.

公开(公告)号：EP2538976B1

公开(公告)日：2016-11-30

申请号：EP11748067.3

申请日：2011-02-24

Applicant: Immunogen, Inc.

Inventor： AB, Olga ,  TAVARES, Daniel ,  RUI, Lingyun ,  PAYNE, Gillian ,  GOLDMAKHER, Viktor S.

IPC: C07K16/28 ,  A61K47/48 ,  A61K39/395

CPC classification number: C07K16/28 ,  A61K31/5365 ,  A61K31/537 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/545 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6889 ,  A61K2039/505 ,  C07H21/00 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94 ,  C12N5/16 ,  C12N15/62 ,  C12N15/63 ,  C12N15/70 ,  C12N15/79 ,  C12N2800/00

Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.

公开(公告)号：EP3041933A1

公开(公告)日：2016-07-13

申请号：EP14842177.9

申请日：2014-09-03

Applicant: Bell Biosystems, Inc.

Inventor： BELL, Caleb, B. ,  BAZAROV, Alexey ,  WAKEEL, Abdul ,  BARROZO, Joyce

IPC: C12N15/03

CPC classification number: C12N5/16 ,  C07K14/195 ,  C07K2319/034 ,  C12N15/87 ,  C12N2510/00

Abstract: The present invention is directed generally to host cells with artificial endosymbionts, wherein the artificial endosymbiont and the host cell communicate with each other to alter a phenotype of the host cell. In some embodiments, the communication comprises the secretion of a polypeptide from the artificial endosymbiont into the host cell. The secreted polypeptide can be a selectable marker, a reporter protein, a transcription factor, a signal pathway protein, a receptor, a growth factor, a cytokine, an effector molecule or other factors that can produce a phenotype in the host cell.

公开(公告)号：EP2929026A1

公开(公告)日：2015-10-14

申请号：EP13859745.5

申请日：2013-12-05

Applicant: The New York Stem Cell Foundation

Inventor： EGLI, Dieter

IPC: C12N15/07

CPC classification number: C12N15/873 ,  A61K35/54 ,  C12N5/0609 ,  C12N5/16 ,  C12N7/00 ,  C12N15/8775 ,  C12N15/8776 ,  C12N2517/04 ,  C12N2517/10 ,  C12N2760/18832

Abstract: The present invention provides modified oocytes having a nuclear genome derived from a first oocyte and cytoplasm derived from a second oocyte from a different subject, and methods for making and using such modified oocytes. The methods and compositions of the present invention can be useful in a variety of settings including, but not limited to, in in vitro fertilization (“IVF”) procedures.

Abstract translation: 本发明提供了具有衍生自来自不同受试者的第二卵母细胞的第一卵母细胞和细胞质的核基因组的修饰的卵母细胞，以及用于制备和使用这些修饰的卵母细胞的方法。 本发明的方法和组合物可用于多种设置，包括但不限于体外受精（“IVF”）程序。

公开(公告)号：EP2738222A4

公开(公告)日：2015-05-06

申请号：EP12817370

申请日：2012-07-11

Applicant: TORAY INDUSTRIES

Inventor： AKITA MASARU ,  NISHIDA SHINGO ,  MATSUOKA HIDEO ,  SUZUKI SHIGEMITSU ,  MORITA YASUFUMI

IPC: C08L101/00 ,  C08K7/04 ,  C08L21/00

CPC classification number: C12N5/166 ,  B29C47/0004 ,  C08J3/20 ,  C08J5/042 ,  C08J5/043 ,  C08J2377/00 ,  C08J2400/202 ,  C08J2433/06 ,  C08K3/013 ,  C08K5/092 ,  C08K7/14 ,  C08L15/00 ,  C08L21/00 ,  C08L23/12 ,  C08L33/068 ,  C08L67/02 ,  C08L67/04 ,  C08L69/00 ,  C08L71/12 ,  C08L77/02 ,  C08L77/06 ,  C08L81/04 ,  C08L101/00 ,  C08L101/005 ,  C08L101/02 ,  C12N5/0691 ,  C12N5/16 ,  C12N2500/46 ,  C12N2501/06 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/73 ,  C12N2501/998 ,  C12N2506/00 ,  C12N2506/30 ,  C08K3/0033

Abstract: Disclosed is a thermoplastic resin composition for impact absorbing members that is obtained by blending 1-200 parts by weight of an inorganic filler (C) to 100 parts by weight in total of 50-80 parts by weight of a thermoplastic resin (A) and 20-50 parts by weight of a gummous polymer (B) having a reactive functional group, wherein: the thermoplastic resin (A) forms a continuous phase; the gummous polymer (B) having a reactive functional group forms a disperse phase; the inorganic filler (C) is dispersed in the continuous phase and/or the disperse phase; the thermoplastic resin composition contains, in the disperse phase (B) of the gummous polymer (B), greater than or equal to 10% by area of particles having particle sizes of 1-100 nm and formed of a compound produced by a reaction between the thermoplastic resin (A) and the gummous polymer (B); and the load-displacement curve at the time of subjecting a square pillar to high-speed compression under specific conditions has a rectangular waveform having high load and large displacement. The present invention provides a thermoplastic resin composition that: is suitable for impact absorbing members; is excellent in strength, rigidity, and heat resistance; and is resistant to breaking upon high-speed compression and can achieve a rectangular waveform having high load, even as a molded product having a simple shape.

公开(公告)号：EP2829608A1

公开(公告)日：2015-01-28

申请号：EP13177678.3

申请日：2013-07-23

Applicant: Universität Bielefeld

Inventor： Krämer, Oliver ,  Klausing, Sandra ,  Noll, Thomas

IPC: C12N15/113 ,  C12N5/071 ,  C12N5/16

CPC classification number: C12N15/113 ,  C07K16/00 ,  C07K2317/14 ,  C12N5/0043 ,  C12N5/0056 ,  C12N5/16 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/00 ,  C12N2501/105 ,  C12N2501/59 ,  C12N2510/02

Abstract: This invention relates to methods for the recombinant expression of a protein of interest in a mammalian host cell, use of an shRNA or an siRNA directed against the Galectin-1 gene for increasing the expression of a protein of interest in a mammalian host cell and kits comprising said shRNA or an siRNA and a CHO cell.

Abstract translation: 本发明涉及在哺乳动物宿主细胞中重组表达目标蛋白的方法，使用针对Galectin-1基因的shRNA或siRNA来增加哺乳动物宿主细胞中目的蛋白质的表达和试剂盒 包含所述shRNA或siRNA和CHO细胞。

公开(公告)号：EP2421958A4

公开(公告)日：2013-09-04

申请号：EP10767783

申请日：2010-04-22

Applicant: UNIV OREGON HEALTH & SCIENCE

Inventor： MITALIPOV SHOUKHRAT M

IPC: C12N5/075 ,  C12N15/00

CPC classification number: C12N5/0609 ,  C12N5/0604 ,  C12N5/16 ,  C12N15/873 ,  C12N15/8775 ,  C12N15/8776 ,  C12N2517/10